The University of Southampton
University of Southampton Institutional Repository

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Aim
There are no approved drugs for the treatment of non-alcoholic fatty liver disease (NAFLD). However, many randomized controlled trials (RCT) have examined the effect of anti-hyperglycaemic agents on NAFLD in patients with and without type 2 diabetes mellitus (T2DM), since both T2DM and insulin resistance are closely linked to this burdensome liver disease.

Methods
We systematically searched publication databases using predefined keywords to identify head-to-head or placebo-controlled RCTs (published until September 30, 2019) of NAFLD individuals testing the efficacy of anti-hyperglycaemic drugs to specifically treat NAFLD or non-alcoholic steatohepatitis (NASH). Outcomes of interest included changes in serum liver enzyme levels, liver fat, liver fibrosis, or histologic resolution of NASH.

Results
We included 29 RCTs involving a total of 2,617 individuals (∼45% had T2DM) that have used metformin (n = 6 studies), glitazones (n = 8 studies), glucagon-like peptide-1 receptor agonists (n = 6 studies), dipeptidyl peptidase-4 inhibitors (n = 4 studies) or sodium-glucose cotransporter-2 inhibitors (n = 7 studies) to treat NAFLD. Although most anti-hyperglycaemic drugs improved serum liver enzyme levels, only glitazones (especially pioglitazone) and liraglutide showed an improvement of histologic features of NAFLD, with a mild beneficial effect also on liver fibrosis for pioglitazone only.

Conclusion
RCT evidence supports the efficacy of some anti-hyperglycaemic agents (especially pioglitazone) in patients with NAFLD or NASH, though weight gain with pioglitazone may warrant caution. Further well-designed RCTs are needed to better characterize the efficacy and safety of monotherapy and combination therapy with anti-hyperglycaemic agents in patients with NAFLD.
Anti-hyperglycaemic drugs, NAFLD, NASH, Type 2 diabetes
1262-3636
427-441
Mantovani, Alessandro
19fc8a1f-60fe-403a-b70e-6b6884929e03
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Scorletti, Eleonora
4e896544-2974-4f81-9696-1595d3c36814
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Mantzoros, Christos S.
e079c112-0163-481c-aea6-1c3d0f68c2a4
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f
Mantovani, Alessandro
19fc8a1f-60fe-403a-b70e-6b6884929e03
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Scorletti, Eleonora
4e896544-2974-4f81-9696-1595d3c36814
Scorletti, Eleonora
42bb0659-ac67-4a73-bf36-a881fe6c1563
Mantzoros, Christos S.
e079c112-0163-481c-aea6-1c3d0f68c2a4
Targher, Giovanni
043e0811-b389-4922-974e-22e650212c5f

Mantovani, Alessandro, Byrne, Christopher, Scorletti, Eleonora, Scorletti, Eleonora, Mantzoros, Christos S. and Targher, Giovanni (2020) Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & Metabolism, 46 (6), 427-441. (doi:10.1016/j.diabet.2019.12.007).

Record type: Article

Abstract

Aim
There are no approved drugs for the treatment of non-alcoholic fatty liver disease (NAFLD). However, many randomized controlled trials (RCT) have examined the effect of anti-hyperglycaemic agents on NAFLD in patients with and without type 2 diabetes mellitus (T2DM), since both T2DM and insulin resistance are closely linked to this burdensome liver disease.

Methods
We systematically searched publication databases using predefined keywords to identify head-to-head or placebo-controlled RCTs (published until September 30, 2019) of NAFLD individuals testing the efficacy of anti-hyperglycaemic drugs to specifically treat NAFLD or non-alcoholic steatohepatitis (NASH). Outcomes of interest included changes in serum liver enzyme levels, liver fat, liver fibrosis, or histologic resolution of NASH.

Results
We included 29 RCTs involving a total of 2,617 individuals (∼45% had T2DM) that have used metformin (n = 6 studies), glitazones (n = 8 studies), glucagon-like peptide-1 receptor agonists (n = 6 studies), dipeptidyl peptidase-4 inhibitors (n = 4 studies) or sodium-glucose cotransporter-2 inhibitors (n = 7 studies) to treat NAFLD. Although most anti-hyperglycaemic drugs improved serum liver enzyme levels, only glitazones (especially pioglitazone) and liraglutide showed an improvement of histologic features of NAFLD, with a mild beneficial effect also on liver fibrosis for pioglitazone only.

Conclusion
RCT evidence supports the efficacy of some anti-hyperglycaemic agents (especially pioglitazone) in patients with NAFLD or NASH, though weight gain with pioglitazone may warrant caution. Further well-designed RCTs are needed to better characterize the efficacy and safety of monotherapy and combination therapy with anti-hyperglycaemic agents in patients with NAFLD.

Text
Glucose-lowering drugs for NAFLD_Systematic review R1 version - Accepted Manuscript
Download (289kB)
Text
Supplementary Figure S1 PRISMA Flow Chart - Accepted Manuscript
Download (119kB)
Text
Supplementary Table S1 R1 version - Accepted Manuscript
Download (109kB)

More information

Accepted/In Press date: 27 December 2019
e-pub ahead of print date: 7 January 2020
Published date: 1 November 2020
Keywords: Anti-hyperglycaemic drugs, NAFLD, NASH, Type 2 diabetes

Identifiers

Local EPrints ID: 436859
URI: http://eprints.soton.ac.uk/id/eprint/436859
ISSN: 1262-3636
PURE UUID: ecf57a85-f3de-48fa-ad95-16e001182ca7
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 13 Jan 2020 17:30
Last modified: 17 Mar 2024 05:11

Export record

Altmetrics

Contributors

Author: Alessandro Mantovani
Author: Eleonora Scorletti
Author: Eleonora Scorletti
Author: Christos S. Mantzoros
Author: Giovanni Targher

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×